Articles published by Almirall

Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business

Today 1:18 EDT

From Almirall

Via Business Wire

Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology

April 13, 2026

From Almirall

Via Business Wire

Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology

March 23, 2026

From Almirall

Via Business Wire

FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2

June 10, 2024

From Almirall

Via Business Wire

Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

December 21, 2023

From Almirall

Via Business Wire

Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

October 11, 2023

From Almirall

Via Business Wire

Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business

July 24, 2023

From Almirall

Via Business Wire

Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Almirall

Via Business Wire

Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc

September 29, 2022

From Almirall

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.